PFG Investments LLC Invests $252,000 in GeneDx Holdings Corp. (NASDAQ:WGS)

PFG Investments LLC purchased a new stake in GeneDx Holdings Corp. (NASDAQ:WGS) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 3,274 shares of the company’s stock, valued at approximately $252,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. MCF Advisors LLC grew its holdings in GeneDx by 107.7% during the 4th quarter. MCF Advisors LLC now owns 351 shares of the company’s stock valued at $27,000 after buying an additional 182 shares in the last quarter. CWM LLC bought a new stake in GeneDx during the 3rd quarter worth approximately $89,000. Evolution Wealth Advisors LLC purchased a new stake in GeneDx in the 4th quarter worth approximately $202,000. Verition Fund Management LLC boosted its holdings in GeneDx by 12.9% in the 3rd quarter. Verition Fund Management LLC now owns 25,845 shares of the company’s stock valued at $1,097,000 after purchasing an additional 2,945 shares during the period. Finally, SG Americas Securities LLC grew its position in shares of GeneDx by 87.2% during the 4th quarter. SG Americas Securities LLC now owns 8,735 shares of the company’s stock valued at $671,000 after purchasing an additional 4,068 shares in the last quarter. 61.72% of the stock is currently owned by institutional investors.

Insider Transactions at GeneDx

In related news, major shareholder School Of Medicine At Mo Icahn sold 126,782 shares of the company’s stock in a transaction on Monday, November 18th. The shares were sold at an average price of $70.78, for a total transaction of $8,973,629.96. Following the completion of the sale, the insider now directly owns 2,719,692 shares in the company, valued at $192,499,799.76. This represents a 4.45 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Katherine Stueland sold 23,108 shares of the firm’s stock in a transaction on Friday, November 15th. The stock was sold at an average price of $70.48, for a total transaction of $1,628,651.84. Following the completion of the sale, the chief executive officer now directly owns 82,318 shares in the company, valued at approximately $5,801,772.64. This trade represents a 21.92 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 363,669 shares of company stock worth $28,061,081. Company insiders own 27.30% of the company’s stock.

GeneDx Stock Down 3.9 %

Shares of NASDAQ WGS opened at $74.85 on Friday. The stock has a market capitalization of $2.06 billion, a P/E ratio of -24.07 and a beta of 2.02. GeneDx Holdings Corp. has a one year low of $3.62 and a one year high of $98.87. The firm’s 50 day simple moving average is $78.29 and its two-hundred day simple moving average is $57.97. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.40 and a quick ratio of 2.27.

GeneDx (NASDAQ:WGS) last issued its earnings results on Tuesday, October 29th. The company reported $0.04 EPS for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.25. GeneDx had a negative net margin of 31.25% and a negative return on equity of 13.35%. The company had revenue of $76.90 million for the quarter, compared to analysts’ expectations of $64.98 million. During the same quarter last year, the company earned ($0.82) EPS. The firm’s revenue was up 44.3% compared to the same quarter last year. As a group, analysts expect that GeneDx Holdings Corp. will post -0.24 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

WGS has been the subject of several research analyst reports. Craig Hallum lifted their price objective on GeneDx from $70.00 to $95.00 and gave the company a “buy” rating in a research note on Wednesday, October 30th. The Goldman Sachs Group boosted their price objective on GeneDx from $54.00 to $70.00 and gave the stock a “neutral” rating in a report on Wednesday, October 30th. Wells Fargo & Company raised their target price on shares of GeneDx from $34.00 to $75.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 30th. Finally, TD Cowen increased their price target on shares of GeneDx from $75.00 to $118.00 and gave the stock a “buy” rating in a report on Tuesday, January 7th. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $70.67.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.